Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

Yoshihiro Komohara, Mamoru Harada, Yoshimi Arima, Shigetaka Suekane, Masanori Noguchi, Akira Yamada, Kyogo Itoh, Kei Matsuoka

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

Original languageEnglish
Pages (from-to)1157-1162
Number of pages6
JournalJournal of Urology
Volume177
Issue number3
DOIs
Publication statusPublished - 2007 Mar 1
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Antigens
Polycomb-Group Proteins
Cytotoxic T-Lymphocytes
HLA Antigens
Multidrug Resistance-Associated Proteins
Peptides
Neoplasms
Cell Line
Blood Cells
T-Lymphocytes
Messenger RNA

Keywords

  • cancer vaccines
  • carcinoma
  • cytotoxic
  • kidney
  • renal cell
  • T-lymphocytes

ASJC Scopus subject areas

  • Urology

Cite this

Komohara, Y., Harada, M., Arima, Y., Suekane, S., Noguchi, M., Yamada, A., ... Matsuoka, K. (2007). Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma. Journal of Urology, 177(3), 1157-1162. https://doi.org/10.1016/j.juro.2006.10.035

Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma. / Komohara, Yoshihiro; Harada, Mamoru; Arima, Yoshimi; Suekane, Shigetaka; Noguchi, Masanori; Yamada, Akira; Itoh, Kyogo; Matsuoka, Kei.

In: Journal of Urology, Vol. 177, No. 3, 01.03.2007, p. 1157-1162.

Research output: Contribution to journalArticle

Komohara, Y, Harada, M, Arima, Y, Suekane, S, Noguchi, M, Yamada, A, Itoh, K & Matsuoka, K 2007, 'Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma', Journal of Urology, vol. 177, no. 3, pp. 1157-1162. https://doi.org/10.1016/j.juro.2006.10.035
Komohara, Yoshihiro ; Harada, Mamoru ; Arima, Yoshimi ; Suekane, Shigetaka ; Noguchi, Masanori ; Yamada, Akira ; Itoh, Kyogo ; Matsuoka, Kei. / Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma. In: Journal of Urology. 2007 ; Vol. 177, No. 3. pp. 1157-1162.
@article{62669318eb3e4b3f97c1e4e58687afff,
title = "Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma",
abstract = "Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.",
keywords = "cancer vaccines, carcinoma, cytotoxic, kidney, renal cell, T-lymphocytes",
author = "Yoshihiro Komohara and Mamoru Harada and Yoshimi Arima and Shigetaka Suekane and Masanori Noguchi and Akira Yamada and Kyogo Itoh and Kei Matsuoka",
year = "2007",
month = "3",
day = "1",
doi = "10.1016/j.juro.2006.10.035",
language = "English",
volume = "177",
pages = "1157--1162",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Identification of Target Antigens in Specific Immunotherapy for Renal Cell Carcinoma

AU - Komohara, Yoshihiro

AU - Harada, Mamoru

AU - Arima, Yoshimi

AU - Suekane, Shigetaka

AU - Noguchi, Masanori

AU - Yamada, Akira

AU - Itoh, Kyogo

AU - Matsuoka, Kei

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

AB - Purpose: Effective immunotherapy against renal cell carcinoma has not yet been established despite recent advances in specific immunotherapy for various malignancies. A plausible reason is limited information about target antigens of renal cell carcinoma. We searched for useful cancer antigens applicable to immunotherapy for renal cell carcinoma by examining antigen expression in renal cell carcinoma cell lines and testing the ability to induce renal cell carcinoma reactive cytotoxic T lymphocytes. Materials and Methods: mRNA expression of a panel of cancer associated antigens was examined using 5 renal cell carcinoma cell lines. Thereafter antigen derived peptides reported to induce cancer reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with cancer were examined for their potential to induce cytotoxic T lymphocytes from peripheral blood mononuclear cells of human leukocyte antigen-A24+ patients with renal cell carcinoma. Results: Three candidate antigens, including multidrug resistance-associated protein 3, polycomb group protein enhancer of zeste homologue 2 and Her2/neu, were expressed in all 5 renal cell carcinoma cell lines. Six peptides derived from these antigens, including multidrug resistance-associated protein 3503-511, multidrug resistance-associated protein 31293-1302, polycomb group protein enhancer of zeste homologue 2291-299, polycomb group protein enhancer of zeste homologue 2735-743, Her2/neu342-350 and Her2/neu485-493, efficiently induced peptide specific and renal cell carcinoma reactive cytotoxic T lymphocytes from human leukocyte antigen-A24+ patients with renal cell carcinoma. Blocking and cold inhibition assays revealed that cytotoxicity against renal cell carcinoma depended on human leukocyte antigen class I restricted and peptide specific CD8+ T cells. Conclusions: This information could facilitate the development of effective immunotherapy against renal cell carcinoma.

KW - cancer vaccines

KW - carcinoma

KW - cytotoxic

KW - kidney

KW - renal cell

KW - T-lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=33846817515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846817515&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.10.035

DO - 10.1016/j.juro.2006.10.035

M3 - Article

C2 - 17296437

AN - SCOPUS:33846817515

VL - 177

SP - 1157

EP - 1162

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -